Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
cancer
7
×
deals
7
×
life sciences
national blog main
national top stories
san francisco blog main
boston blog main
boston top stories
san diego blog main
san diego top stories
san francisco top stories
startups
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
clinical trials
eli lilly
investing
johnson & johnson
abbvie
alzheimer's disease
merck
nonalcoholic steatohepatitis
novartis
What
drug
7
×
roundup
bio
companies
cancer
nash
new
news
price
today
acquisitions
advance
ahead
alzheimer’s
ambien
american
annual
approval
approved
asco
attendees
attention
biggest
biogen’s
biologic
biology
biopharmaceutical
biotech
build
buy
camp’s
cash
ceo
chicago
city
clinical
combinations
community’s
company’s
convo
Language
unset
Current search:
cancer
×
drug
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
@xconomy.com
6 years ago
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs